Solventum Corporation (NYSE:SOLV) Receives $83.67 Consensus PT from Brokerages

Shares of Solventum Corporation (NYSE:SOLVGet Free Report) have received a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $81.9091.

Several equities research analysts recently commented on SOLV shares. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Thursday, May 14th. Wells Fargo & Company decreased their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Wedbush assumed coverage on shares of Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 target price on the stock. BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. Finally, Rothschild & Co Redburn started coverage on shares of Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company.

Get Our Latest Research Report on Solventum

Institutional Investors Weigh In On Solventum

Large investors have recently added to or reduced their stakes in the stock. Hilltop National Bank lifted its holdings in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. CrossGen Wealth LLC purchased a new stake in Solventum during the fourth quarter valued at $25,000. Measured Wealth Private Client Group LLC purchased a new stake in Solventum during the third quarter valued at $25,000. Clearstead Trust LLC lifted its holdings in Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after acquiring an additional 150 shares during the period. Finally, JNBA Financial Advisors boosted its position in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares during the last quarter.

Solventum Price Performance

Shares of NYSE SOLV opened at $81.46 on Tuesday. The firm has a market cap of $14.11 billion, a P/E ratio of 9.98, a PEG ratio of 1.21 and a beta of 0.66. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a 50 day moving average of $76.93 and a 200 day moving average of $74.22.

Solventum (NYSE:SOLVGet Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the business posted $1.34 EPS. The company’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Featured Articles

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.